-
Je něco špatně v tomto záznamu ?
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
SH. Desai, MA. Spinner, AM. Evens, A. Sykorova, V. Bachanova, G. Goyal, B. Kahl, K. Dorritie, J. Azzi, VP. Kenkre, C. Chang, J. Michalka, SM. Ansell, B. Fusco, N. Sumransub, H. Hatic, R. Saba, U. Ibrahim, EI. Harris, H. Shah, N. Wagner-Johnston,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu multicentrická studie, časopisecké články
NLK
Directory of Open Access Journals
od 2016
PubMed Central
od 2016
Europe PubMed Central
od 2016
ROAD: Directory of Open Access Scholarly Resources
od 2016
- MeSH
- brentuximab vedotin MeSH
- dospělí MeSH
- Hodgkinova nemoc * terapie MeSH
- imunokonjugáty * MeSH
- kojenec MeSH
- lidé MeSH
- retrospektivní studie MeSH
- transplantace kmenových buněk MeSH
- Check Tag
- dospělí MeSH
- kojenec MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.
Cleveland Clinic Foundation Cleveland OH
Department of Clinical Hematology Charles University Prague Prague Czech Republic
Department of Hematology and Medical Oncology Winship Cancer Institute Emory University Atlanta GA
Department of Medicine Rutgers Cancer Institute of New Jersey New Brunswick NJ
Division of Hematology and Oncology Department of Medicine UPMC Hillman Cancer Center Pittsburgh PA
Division of Hematology Mayo Clinic Rochester MN
Division of Hematology Oncology and Transplantation University of Minnesota Minneapolis MN
Division of Oncology Department of Medicine Stanford University Medical Center Stanford CA
Division of Oncology Department of Medicine Washington University School of Medicine St Louis MO
Icahn School of Medicine Mount Sinai New York NY
Perlmutter Cancer Center NYU Grossman Medical School New York NY
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore MD
University Hospital and Faculty of Medicine Hradec Kralove Hradec Kralove Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000258
- 003
- CZ-PrNML
- 005
- 20240213093034.0
- 007
- ta
- 008
- 240109s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1182/bloodadvances.2023011205 $2 doi
- 035 __
- $a (PubMed)37729621
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Desai, Sanjal H $u Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN $u Division of Hematology, Mayo Clinic, Rochester, MN $1 https://orcid.org/0000000278922625
- 245 10
- $a Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era / $c SH. Desai, MA. Spinner, AM. Evens, A. Sykorova, V. Bachanova, G. Goyal, B. Kahl, K. Dorritie, J. Azzi, VP. Kenkre, C. Chang, J. Michalka, SM. Ansell, B. Fusco, N. Sumransub, H. Hatic, R. Saba, U. Ibrahim, EI. Harris, H. Shah, N. Wagner-Johnston, S. Arai, GS. Nowakowski, H. Mocikova, D. Jagadeesh, KA. Blum, C. Diefenbach, S. Iyengar, KC. Rappazzo, F. Baidoun, Y. Choi, V. Prochazka, RH. Advani, I. Micallef
- 520 9_
- $a In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a Hodgkinova nemoc $x terapie $7 D006689
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a imunokonjugáty $7 D018796
- 650 _2
- $a brentuximab vedotin $7 D000079963
- 650 _2
- $a transplantace kmenových buněk $7 D033581
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Spinner, Michael A $u Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA
- 700 1_
- $a Evens, Andrew M $u Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ $1 https://orcid.org/0000000269001824
- 700 1_
- $a Sykorova, Alice $u University Hospital and Faculty of Medicine, Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Bachanova, Veronika $u Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
- 700 1_
- $a Goyal, Gaurav $u Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL $1 https://orcid.org/0000000161485177
- 700 1_
- $a Kahl, Brad $u Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
- 700 1_
- $a Dorritie, Kathleen $u Division of Hematology & Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA $1 https://orcid.org/0000000208638573
- 700 1_
- $a Azzi, Jacues $u Icahn School of Medicine Mount Sinai, New York, NY
- 700 1_
- $a Kenkre, Vaishalee P $u Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI
- 700 1_
- $a Chang, Cheryl $u Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA
- 700 1_
- $a Michalka, Jozef $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Ansell, Stephen M $u Division of Hematology, Mayo Clinic, Rochester, MN
- 700 1_
- $a Fusco, Brendon $u Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
- 700 1_
- $a Sumransub, Nuttavut $u Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN $1 https://orcid.org/0000000174560623
- 700 1_
- $a Hatic, Haris $u Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
- 700 1_
- $a Saba, Raya $u Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
- 700 1_
- $a Ibrahim, Uroosa $u Icahn School of Medicine Mount Sinai, New York, NY $1 https://orcid.org/0000000300885438
- 700 1_
- $a Harris, Elyse I $u Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI
- 700 1_
- $a Shah, Harsh $u Division of Hematology, Department of Medicine, Hunstman Cancer Institute, The University of Utah, Salt Lake City, UT
- 700 1_
- $a Wagner-Johnston, Nina $u The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD $1 https://orcid.org/0000000165299793
- 700 1_
- $a Arai, Sally $u Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA $1 https://orcid.org/0000000319934172
- 700 1_
- $a Nowakowski, Grzegorz S $u Division of Hematology, Mayo Clinic, Rochester, MN
- 700 1_
- $a Mocikova, Heidi $u Department of Clinical Hematology, Charles University in Prague, Prague, Czech Republic $1 https://orcid.org/0000000320340769
- 700 1_
- $a Jagadeesh, Deepa $u Cleveland Clinic Foundation, Cleveland, OH
- 700 1_
- $a Blum, Kristie A $u Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
- 700 1_
- $a Diefenbach, Catherine $u Perlmutter Cancer Center, NYU Grossman Medical School, New York, NY
- 700 1_
- $a Iyengar, Siddharth $u Division of Hematology, Department of Medicine, Hunstman Cancer Institute, The University of Utah, Salt Lake City, UT
- 700 1_
- $a Rappazzo, K C $u The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
- 700 1_
- $a Baidoun, Firas $u Cleveland Clinic Foundation, Cleveland, OH
- 700 1_
- $a Choi, Yun $u Perlmutter Cancer Center, NYU Grossman Medical School, New York, NY
- 700 1_
- $a Prochazka, Vit $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic $1 https://orcid.org/0000000298613117 $7 xx0143822
- 700 1_
- $a Advani, Ranjana H $u Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA
- 700 1_
- $a Micallef, Ivana $u Division of Hematology, Mayo Clinic, Rochester, MN
- 773 0_
- $w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 7, č. 23 (2023), s. 7295-7303
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37729621 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093032 $b ABA008
- 999 __
- $a ok $b bmc $g 2049120 $s 1209952
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 7 $c 23 $d 7295-7303 $e 2023Dec12 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
- LZP __
- $a Pubmed-20240109
